Presentation of MRS 2022 results (2nd part) - Pharmaceutical Companies
The health emergency caused by COVID in 2020 was a real challenge for the health system as a whole, including companies in the pharmaceutical sector, which faced the challenges of the pandemic in what has been one of the greatest research challenges in the history.
Many of these companies made all their resources and developments available to society, including the vaccines that have saved so many lives, and this translated into a recognition that is maintained over time, as shown by the 8th edition of the Health Reputation Monitor, in which Pfizer (1st), Novartis (2nd) and Janssen (3rd) repeat as the pharmaceutical companies with the best reputation in Spain for the second consecutive edition. Once again it is demonstrated that a committed performance in the most difficult moments translates into consolidated leadership.
Completing the top ten of the general ranking of pharmaceutical companies with the best reputation are Astrazeneca (4th), GSK (5th), Lilly (6th), Roche (7th), Bayer (8th), AbbVie (9th) and Sanofi (10th).
On the other hand, the Health Reputation Monitor (MRS) also presents other rankings, among which are the companies with the best reputation and most innovative by therapeutic areas; the best health technology companies, led by Siemens (1st), Philips (2nd) and General Electric (3rd); and the ranking of the most reputable biomedical device manufacturers, led by KLS Martin (1st) Depuy Synthes (2nd) and Stryker (3rd).
The Health Reputation Monitor (MRS) is the only independent study that analyzes the reputation of all Spanish health. To achieve this, a verification process has been carried out with three phases: the first, the assessment carried out by medical professionals from 26 specialties -started in April 2022-; the second, the assessment of hospital managers and managers, nurses, nurse managers, pharmaceutical company managers, hospital pharmacy managers, patient associations, journalists and health informants, as well as members of the public health administration - which began in May from 2022-; In addition, these evaluations are complemented by a third analysis: an objective evaluation of reputational merits carried out by the Merco technicians, responsible for the MRS field work.
The production process has been subjected to an independent review by KPMG in accordance with the ISAE 3000 standard, and has the endorsement of the collegiate organizations of doctors and nurses, as well as the associations of patients and health journalists.
Press release MRS 2022 Pharmaceutical Companies (PDF, 261Kb)
Results presentation MRS 2022 Pharmaceutical Companies (PDF, 2324Kb)